130 related articles for article (PubMed ID: 18568272)
21. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
[TBL] [Abstract][Full Text] [Related]
22. HIV type 1 drug resistance in adults receiving highly active antiretroviral therapy in Abidjan, Côte d'Ivoire.
Hanson DL; Adjé-Touré C; Talla-Nzussouo N; Eby P; Borget MY; Kouadio LY; Celestin BE; Tossou O; Eholie S; Kadio A; Chorba T; Nkengasong JN
AIDS Res Hum Retroviruses; 2009 May; 25(5):489-95. PubMed ID: 19388820
[TBL] [Abstract][Full Text] [Related]
23. Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire.
Chaix ML; Rouet F; Kouakoussui KA; Laguide R; Fassinou P; Montcho C; Blanche S; Rouzioux C; Msellati P
Pediatr Infect Dis J; 2005 Dec; 24(12):1072-6. PubMed ID: 16371868
[TBL] [Abstract][Full Text] [Related]
24. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.
Phillips AN; Staszewski S; Weber R; Kirk O; Francioli P; Miller V; Vernazza P; Lundgren JD; Ledergerber B; ; ;
JAMA; 2001 Nov; 286(20):2560-7. PubMed ID: 11722270
[TBL] [Abstract][Full Text] [Related]
25. CD4+ T-lymphocytes natural decrease in HAART-naïve HIV-infected adults in Abidjan.
Duvignac J; Anglaret X; Kpozehouen A; Inwoley A; Seyler C; Toure S; Gourvellec G; Messou E; Gabillard D; Thiébaut R
HIV Clin Trials; 2008; 9(1):26-35. PubMed ID: 18215979
[TBL] [Abstract][Full Text] [Related]
26. 24-Month Clinical, Immuno-Virological Outcomes, and HIV Status Disclosure in Adolescents Living With Perinatally-Acquired HIV in the IeDEA-COHADO Cohort in Togo and Côte d'Ivoire, 2015-2017.
Dassi Tchoupa Revegue MH; Takassi UE; Tanoh Eboua F; Desmonde S; Amoussou-Bouah UB; Bakai TA; Jesson J; Dahourou DL; Malateste K; Aka-Dago-Akribi H; Raynaud JP; Arrivé E; Leroy V
Front Pediatr; 2021; 9():582883. PubMed ID: 34277512
[No Abstract] [Full Text] [Related]
27. Body mass index, proteinuria and total lymphocyte counts in predicting treatment responses among ART naïve individuals with HIV initiated on antiretroviral treatment in Dar es Salaam, Tanzania, 2019: a cohort study.
Munseri P; Jassely L; Tumaini B; Hertzmark E
BMJ Open; 2022 Jun; 12(6):e059193. PubMed ID: 35676009
[TBL] [Abstract][Full Text] [Related]
28. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
29. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial.
Danel C; Moh R; Minga A; Anzian A; Ba-Gomis O; Kanga C; Nzunetu G; Gabillard D; Rouet F; Sorho S; Chaix ML; Eholié S; Menan H; Sauvageot D; Bissagnene E; Salamon R; Anglaret X;
Lancet; 2006 Jun; 367(9527):1981-9. PubMed ID: 16782488
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa.
De Luca A; Marazzi MC; Mancinelli S; Ceffa S; Altan AM; Buonomo E; Prosperi MC; Pedruzzi B; Noorjehan AM; Scarcella P; Liotta G; Palombi L
J Acquir Immune Defic Syndr; 2012 Mar; 59(3):236-44. PubMed ID: 22327246
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa.
Barth RE; van der Meer JT; Hoepelman AI; Schrooders PA; van de Vijver DA; Geelen SP; Tempelman HA
Eur J Clin Microbiol Infect Dis; 2008 Oct; 27(10):977-84. PubMed ID: 18629557
[TBL] [Abstract][Full Text] [Related]
32. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants.
Toure S; Kouadio B; Seyler C; Traore M; Dakoury-Dogbo N; Duvignac J; Diakite N; Karcher S; Grundmann C; Marlink R; Dabis F; Anglaret X;
AIDS; 2008 Apr; 22(7):873-82. PubMed ID: 18427206
[TBL] [Abstract][Full Text] [Related]
33. Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort.
Amani-Bosse C; Dahourou DL; Malateste K; Amorissani-Folquet M; Coulibaly M; Dattez S; Emieme A; Barry M; Rouzioux C; N'gbeche S; Yonaba C; Timité-Konan M; Mea V; Ouédraogo S; Blanche S; Meda N; Seguin-Devaux C; Leroy V
J Int AIDS Soc; 2017 Apr; 20(1):21362. PubMed ID: 28453240
[TBL] [Abstract][Full Text] [Related]
34. CD4 cell response before and after HAART initiation according to viral load and growth indicators in HIV-1-infected children in Abidjan, Côte d'Ivoire.
De Beaudrap P; Rouet F; Fassinou P; Kouakoussui A; Mercier S; Ecochard R; Msellati P
J Acquir Immune Defic Syndr; 2008 Sep; 49(1):70-6. PubMed ID: 18667922
[TBL] [Abstract][Full Text] [Related]
35. Changes in viral load in people with virological failure who remain on the same HAART regimen.
Cozzi-Lepri A; Phillips AN; Miller V; Katlama C; Ledergerber B; Vella S; Weber J; Bruun JN; Kirk O; Clotet B; Lundgrens JD
Antivir Ther; 2003 Apr; 8(2):127-36. PubMed ID: 12741625
[TBL] [Abstract][Full Text] [Related]
36. Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression.
Byakwaga H; Murray JM; Petoumenos K; Kelleher AD; Law MG; Boyd MA; Emery S; Mallon PW; Cooper DA
AIDS Res Hum Retroviruses; 2009 Jun; 25(6):756-76. PubMed ID: 19500017
[TBL] [Abstract][Full Text] [Related]
37. Changes in levels of immune activation and reconstitution markers among HIV-1-infected Africans receiving antiretroviral therapy.
Koblavi-Dème S; Maran M; Kabran N; Borget MY; Kalou M; Kestens L; Maurice C; Sassan-Morokro M; Ekpini ER; Roels TH; Chorba T; Nkengasong JN
AIDS; 2003 Jul; 17 Suppl 3():S17-22. PubMed ID: 14565605
[TBL] [Abstract][Full Text] [Related]
38. Variation of CD4 count and percentage during pregnancy and after delivery: implications for HAART initiation in resource-limited settings.
Ekouevi DK; Inwoley A; Tonwe-Gold B; Danel C; Becquet R; Viho I; Rouet F; Dabis F; Anglaret X; Leroy V
AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1469-74. PubMed ID: 18160003
[TBL] [Abstract][Full Text] [Related]
39. Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia.
Aghokeng AF; Monleau M; Eymard-Duvernay S; Dagnra A; Kania D; Ngo-Giang-Huong N; Toni TD; Touré-Kane C; Truong LX; Delaporte E; Chaix ML; Peeters M; Ayouba A;
Clin Infect Dis; 2014 Jan; 58(1):99-109. PubMed ID: 24076968
[TBL] [Abstract][Full Text] [Related]
40. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
